NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
HeartBeam Inc. (NASDAQ: BEAT) Cardiac Care Technology FAQ
TL;DR
HeartBeam's portable ECG technology provides a competitive edge by enabling early atrial fibrillation detection outside clinical settings, potentially reducing healthcare costs.
HeartBeam's credit card-sized device uses proprietary software to capture 3D heart signals and synthesize them into clinical-grade 12-lead ECGs for remote cardiac monitoring.
HeartBeam's portable ECG technology improves cardiac care accessibility, enabling better heart health management and potentially saving lives through early detection outside hospitals.
HeartBeam created a credit card-sized device that captures 3D heart signals to generate full 12-lead ECGs, revolutionizing portable cardiac diagnostics with 17 patents.
Found this article helpful?
Share it with your network and spread the knowledge!
HeartBeam is a medical technology company that has developed a credit card-sized device and proprietary synthesis software capable of capturing heart signals in three dimensions and converting them into a full synthesized 12-lead ECG.
The technology brings clinical-grade cardiac diagnostics into the hands of patients wherever they are, positioning HeartBeam at the forefront of a revolution in heart health that could greatly impact lives, reduce costs, and redefine the future of cardiac care.
The technology captures the heart's electrical signals from three dimensions using a portable, credit card-sized device and proprietary synthesis software that converts these signals into a full synthesized 12-lead ECG.
The technology is specifically mentioned for detecting and managing atrial fibrillation (AF), and physicians can use it to identify cardiac health trends and acute conditions.
The platform technology is designed for portable devices that can be used wherever the patient is, allowing cardiac diagnostics to be performed outside of medical facilities.
The technology enables physicians to identify cardiac health trends and acute conditions, direct patients to appropriate care outside medical facilities, and provides actionable heart intelligence wherever the patient is located.
HeartBeam holds 13 U.S. and 4 international-issued patents related to their technology enablement.
For more information, visit www.HeartBeam.com or access the company's newsroom at https://ibn.fm/BEAT for the latest news and updates.
Unlike traditional ECG systems that require cables and medical facility settings, HeartBeam's technology is cable-free, portable, and can be used anywhere by patients to deliver clinical-grade cardiac diagnostics.
According to the content, HeartBeam is 'on the verge of transforming how atrial fibrillation is detected and managed' and is 'creating the first-ever cable-free 12-lead ECG' capable of 3D heart signal capture.
Curated from InvestorBrandNetwork (IBN)
